Table 5.
Comparison of in-hospital treatment and outcomes between patients alive and dead during hospitalization.
| Alive (n = 549) |
Dead (n = 74) |
p-Value | |
|---|---|---|---|
| Tocilizumab | 96 (17.5) | 9 (12.2) | 0.25 |
| No hydroxychloroquine or azithromycin | 9 (1.6) | 7 (9.5) | <0.001 |
| Hydroxychloroquine | 12 (2.2) | 4 (5.4) | |
| Azithromycin | 6 (1.1) | 4 (5.4) | |
| Hydroxychloroquine + Azithromycin | 522 (95.1) | 59 (79.7) | |
| Oxygen support | 324 (59.0) | 53 (71.6) | <0.001 |
| High Flow Nasal Cannula | 9 (1.6) | 1 (1.4) | |
| Non-invasive ventilation | 20 (3.6) | 8 (10.8) | |
| Intubation and invasive ventilation | 33 (6.0) | 11 (14.9) | |
| QTc prolongation during hospitalization | 143 (66.5) | 25 (83.3) | 0.045 |
| Longest QTc duration, milliseconds | 460.3 ± 45.3 | 499.0 ± 58.2 | <0.001 |
| Length of hospitalization, days | 10 (5–20) | 6 (3–16) | 0.007 |
Results are expressed as mean ± standard deviation, median and (interquartile range) or number and (percentage).